

# Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

Curtis A. Lachowicz,<sup>1</sup> Sanam Loghavi,<sup>2</sup> Tapan M. Kadia,<sup>3</sup> Naval Daver,<sup>3</sup> Gautam Borthakur,<sup>3</sup> Naveen Pemmaraju,<sup>3</sup> Kiran Naqvi,<sup>3</sup> Yesid Alvarado,<sup>3</sup> Musa Yilmaz,<sup>3</sup> Nicholas Short,<sup>3</sup> Maro Ohanian,<sup>3</sup> Sherry R. Pierce,<sup>3</sup> Keyur P. Patel,<sup>2</sup> Wei Qiao,<sup>4</sup> Jing Ning,<sup>4</sup> Koji Sasaki,<sup>3</sup> Koichi Takahashi,<sup>3</sup> Elias Jabbour,<sup>3</sup> Michael Andreeff,<sup>3</sup> Farhad Ravandi,<sup>3</sup> Hagop M. Kantarjian,<sup>3</sup> Marina Konopleva,<sup>3,\*</sup> and Courtney D. DiNardo<sup>3,\*</sup>

<sup>1</sup>Division of Cancer Medicine, <sup>2</sup>Department of Hematopathology, Division of Pathology and Laboratory Medicine, <sup>3</sup>Department of Leukemia, Division of Cancer Medicine, and

<sup>4</sup>Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX

## Key Points

- VEN in combination with HMAs is highly effective for AML with mutant NPM1 (*NPM1*<sup>+</sup>).
- VEN with HMA therapy could be considered a mutation-targeted treatment in older patients with *NPM1*<sup>+</sup> AML.

Nucleophosmin-1 mutations (*NPM1*<sup>+</sup>) occur in ~30% of acute myeloid leukemia (AML) patients. Although typically associated with favorable prognosis, the beneficial impact of *NPM1*<sup>+</sup> decreases with increasing age in patients treated with standard intensive chemotherapy (IC) or hypomethylating agents (HMAs). This retrospective analysis compared outcomes of *NPM1*<sup>+</sup> AML patients treated with 1 of 3 induction approaches: HMA plus BCL-2 inhibitor venetoclax (VEN), HMA, or IC therapy. Composite complete response (CR<sub>c</sub>: CR + CR with incomplete count recovery) was seen in 96% (27/28), 36% (17/47), and 89% (204/228) of HMA + VEN, HMA, and IC patients, respectively (HMA + VEN vs HMA, *P* < .001; HMA + VEN vs IC, *P* = .10). Older patients (age >65 years) treated with HMA + VEN, HMA, or IC had CR rates of 88%, 28%, and 56%, respectively (HMA + VEN vs HMA, *P* < .001; HMA + VEN vs IC, *P* = .01). Significant improvement in overall survival (OS) was seen in patients age >65 years treated with HMA + VEN vs HMA (not reached [NR] vs 0.4 years; *P* < .001) or IC (NR vs 0.93 years; *P* = .001). Older patients treated with HMA + VEN had OS of 80% after median 1-year follow-up, with estimated 2-year OS of 70%. In the multivariable Cox model analysis, HMA + VEN was associated with a 69% lower risk of death compared with IC (hazard ratio, 0.31; 95% confidence interval, 0.12-0.83; type I error-adjusted *P* = .038). HMA + VEN combinations demonstrated impressive results compared with traditional standard-of-care regimens in older patients with *NPM1*<sup>+</sup> AML.

## Introduction

Nucleophosmin-1 (NPM1) is a multifunctioning molecular chaperone involved in epigenetic cellular regulation through nuclear-cytoplasmic protein shuttling, ribosomal assembly, and maintenance of cellular senescence via interaction with the tumor suppressor p53.<sup>1,2</sup> Mutations in *NPM1* (*NPM1*<sup>+</sup>) occur in ~30% of patients with acute myeloid leukemia (AML) and historically are associated with favorable response to standard intensive chemotherapy (IC), with both increased complete response (CR) rates and improved overall survival (OS).<sup>3,4</sup> *NPM1*<sup>+</sup> is the second most common identified mutation in AML, and the incidence of *NPM1*<sup>+</sup> is not age dependent.<sup>3,5</sup> *NPM1* mutations are enriched in cytogenetically normal AML, where they are identified in ~40% to 60% of cases, occurring at a similar if not increased frequency in older adults.<sup>2,4,6-8</sup> In a large cohort of 1540 AML patients, *NPM1*<sup>+</sup> was a favorable prognostic marker, associated with a hazard ratio (HR) of death of 0.7 (95% confidence interval [CI], 0.6-0.9) and a median OS of nearly 6 years compared with ~2 years in those with wild-type

Submitted 20 November 2019; accepted 19 February 2020; published online 6 April 2020. DOI 10.1182/bloodadvances.2019001267.

\*M.K. and C.D.D. share last authorship.

Send data sharing requests via e-mail to the corresponding author, Courtney D. DiNardo (cdinardo@mdanderson.org).

The full-text version of this article contains a data supplement.

© 2020 by The American Society of Hematology

**Table 1. Patient demographics**

Treatment Group (N = 288)	HMA + VEN (n = 28)	HMA (n = 47)	Intensive induction (n = 228)	P
<b>Median age, y</b>	71	72	55	.0001
<55	—	—	114	
55-65	2	8	89	
>65	26 (median, 72)	39 (median, 75)	25 (median, 68)	.004*
<b>Performance status</b>				
0-1	15 (63)	23 (64)	180 (87)	.0002
2-3	9 (37)	13 (36)	27 (13)	
<b>AML subtype</b>				
De novo	25 (89)	35 (74)	213 (93)	.001
Secondary AML	1 (4)	6 (13)	4 (2)	—
Treated secondary AML	2 (7)	6 (13)	11 (5)	—
<b>Risk group (ELN)</b>				
Favorable	24 (86)	33 (70)	183 (80)	.310
Intermediate	—	5 (11)	12 (5)	—
Adverse	4 (14)	9 (19)	33 (15)	—
<b>Cytogenetics</b>				
Diploid	23 (82)	28 (60)	173 (76)	.331
Complex	1 (4)	2 (4)	8 (4)	—
+8	2 (8)	1 (2)	7 (3)	
−5q	—	—	—	
−7q	—	—	1 (<1)	
−5/−7	—	—	—	
11q abnormality	—	—	1 (<1)	
Other intermediate	2 (7)	11 (23)	23 (1)	
Insufficient/not performed	—	5 (11)	11 (5)	
CBF (inv(16), t(8;21))	—	—	4 (2)	

Data are n or n (%) unless otherwise noted.

\*HMA + VEN vs IC.

(WT) *NPM1*.<sup>3</sup> Felini et al<sup>2</sup> found *NPM1*<sup>+</sup> patients (n = 79; median age at diagnosis, 51.8 years) achieved a CR rate of 77% and harbored less chemotherapy-refractory disease (*NPM1*<sup>+</sup>, 9% vs WT *NPM1*, 23%) after induction therapy. The favorable prognostic impact of *NPM1*<sup>+</sup> seems to be most pronounced in younger patients. A 2012 analysis by Mrozek et al<sup>7</sup> demonstrated younger patients with *NPM1*<sup>+</sup> (median age, 44 years) vs older (median age, 69 years) had profound differences in OS between cohorts (median OS: younger, 10.5 years vs older, 1.7 years). Despite such age-associated prognostic differences, current National Comprehensive Cancer Network and European LeukemiaNet (ELN) guidelines stratify patients with *NPM1*<sup>+</sup> and WT *FLT3* into a favorable risk group (signifying a <40% risk of relapse) when treated with intensive induction therapy.<sup>9,10</sup>

Recent work investigating the prognostic impact of *NPM1*<sup>+</sup> stratified by patients receiving IC age 55 to 65 years or age >65 years found improved OS in *NPM1*<sup>+</sup> patients age 55 to 65 years without cooccurring mutations in *FLT3* internal tandem duplication (ITD; *FLT3*<sup>+</sup>).<sup>11</sup> The favorable impact of *NPM1*<sup>+</sup> seemed to diminish in patients age >65 years, who had lower CR rates (53% vs 88%) and increased 1-year relapse rates

(47% vs 12%) compared with patients age 55 to 65 years, despite similar molecular profiles and cytogenetic risk.<sup>11</sup> In addition to the known prognostic impact of cooccurring mutations, increased *NPM1*<sup>+</sup> variant allele frequency (VAF) may further negate the positive prognostic impact of *NPM1*<sup>+</sup>; however, current data supporting this are conflicting.<sup>12-14</sup>

Although hypomethylating agent (HMA) therapy represents a viable alternative to IC in the unfit older adult, outcomes with HMA monotherapy remain poor, with a median OS of 5.5 months and a 1-year OS of 28%.<sup>15</sup> In *NPM1*<sup>+</sup> patients considered unfit for intensive induction treated with a frontline HMA, responses remain poor (overall response rate, 45.5%; CR, 23.5%; median OS, ~10 months), similar to those seen in a matched WT *NPM1* cohort and consistent with prior studies of patients with intermediate- and poor-risk cytogenetics.<sup>16,17</sup> Efforts to increase responses with IC included in vitro studies using all-trans retinoic acid (ATRA) in conjunction with IC, demonstrating potentiation of the effect of IC.<sup>18</sup> ATRA + IC demonstrated improved responses in *NPM1*<sup>+</sup> AML without cooccurring *FLT3*-ITD in a prior retrospective analysis,<sup>19</sup> an effect that has since yielded mixed results in clinical practice.<sup>20</sup>

**Table 2. Mutational profile**

Key molecular mutations	HMA + VEN	HMA	Intensive induction
Median mutations per patient (range)	4 (1-9)	4 (1-7)	3 (1-11)
<i>FLT3</i> -ITD	4 (18)	28 (60)	100 (44)
<b>AR &gt;0.5, n (by age, y)</b>			
<55	—	—	9
55-65	—	1	5
>65	—	7	3
<b>AR &lt;0.5, n (by age, y)</b>			
<55	—	—	45
55-65	1	2	27
>65	3	18	10
Total evaluable <i>FLT3</i> -ITD	4/4 (100)	28/28 (100)	99/100 (99)
<i>FLT3</i> -D835	3 (7)	5 (11)	42 (18)
<i>DNMT3A</i>	14 (50)	18 (38)	62 (27)
<i>FLT3/IDNMT3A</i>	1 (4)	13 (28)	30 (13)
<i>IDH1</i>	7 (25)	9 (20)	28 (12)
<i>IDH2</i>	7 (25)	7 (15)	44 (19)

Data are n (%) or n/N (%) unless otherwise noted.

The recent approval of venetoclax (VEN; 400 mg daily), an oral BCL-2 inhibitor, in combination with HMAs in older, chemotherapy-unfit AML patients has demonstrated remarkable effectiveness (composite CR [CR<sub>c</sub>; CR + CR with incomplete count recovery (CR<sub>i</sub>)], 73%; OS, 16.9 months),<sup>21</sup> quickly emerging as a new standard of care for the older AML patient. *NPM1*<sup>+</sup> patients seem to particularly benefit from this induction approach, with a CR + CR<sub>i</sub> rate of 91.5%<sup>21</sup> and median OS not reached (NR) at follow-up (median OS, 11 months to NR), an improvement when compared with historical outcomes seen with IC for *NPM1*<sup>+</sup> older patients.

Determining the optimal treatment regimen for an older patient with *NPM1*<sup>+</sup> AML remains a challenging clinical decision. To improve our understanding of outcomes in older patients with *NPM1*<sup>+</sup> AML in the current treatment era, we retrospectively evaluated outcomes of this unique AML cohort when treated with frontline intensive induction therapy, HMA, or HMA + VEN regimens.

## Materials and methods


### Study design and patient selection

Patients with a diagnosis of AML with *NPM1*<sup>+</sup> who received frontline AML therapy at MD Anderson Cancer Center from 2007 to 2019 were eligible for this institutional review board–approved retrospective cohort review. Participants were stratified into cohorts based on the per-protocol induction therapy received: HMA + VEN, HMA, or IC (defined as receipt of cytarabine + anthracycline). Patients treated with IC in combination with targeted therapeutics (ie, *FLT3*, *IDH1*, *IDH2* inhibitors) were included, and additional chemotherapeutic agents such as fludarabine or cladribine were allowed (supplemental Appendix A provides a list of treatment regimens received). HMA patients included those treated with HMA monotherapy (azacitidine or decitabine) or with the combination of an *FLT3* inhibitor (*FLT3i*).

### Data collection and analysis

Patient data were reviewed for age at diagnosis, Eastern Cooperative Oncology Group performance status, ELN risk classification, treatment start date, induction therapy received, history of an antecedent hematological disorder and any previous treatments received for an antecedent hematological disorder, date of relapse, and date of death or last follow-up date. Cytogenetic and molecular data were analyzed at diagnosis, using standard metaphase cytogenetics and targeted molecular testing. All patients had assessment of at least *NPM1* and *FLT3*-ITD. *NPM1* mutation analysis was performed by polymerase chain reaction followed by capillary electrophoresis in 127 patients and by targeted hotspot next-generation sequencing (Illumina, San Diego, CA) in 176 patients. Measurable residual disease (MRD) status in patients obtaining CR/CR<sub>i</sub> was assessed by 8-color multiparameter flow cytometry using leukemia-associated phenotypes and/or variation from normal. Response to therapy was assessed using ELN criteria.<sup>9</sup> OS was calculated as time from start of induction therapy to the date of death or last follow-up. Patients alive at last follow-up were censored in survival analysis.

Patient characteristics were summarized with descriptive statistics and compared among different treatment groups. Continuous variables were compared between treatment groups by a 2-sample Student *t* test or analysis of variance if the data were normally distributed; otherwise, a Wilcoxon rank sum test or Kruskal-Wallis test was used. The association of treatment groups and other clinical factors were assessed using Fisher's exact test or the  $\chi^2$  test. OS was estimated using the Kaplan-Meier method and compared among groups using the log-rank test. Multivariable logistic regression models and Cox proportional hazards models were used to evaluate effects of treatment after adjusting for other risk factors. To account for multiple comparisons, adjusted *P* values were determined for CR<sub>c</sub>, MRD, and OS for the 3 cohorts using



**Figure 1. Mutational profiles of HMA + VEN, HMA, and IC (age >65 years) cohorts.** HMA + VEN (A), HMA (B), and IC (C) cohorts harbored diverse mutational profiles with a median of 4 mutations per patient, including *NPM1*<sup>+</sup>. Commonly cooccurring mutations in the context of *NPM1* mutations included *FLT3-ITD*, *DNMT3A*, *IDH1*, and *IDH2*. *TET2* mutations were common in the HMA + VEN and HMA cohorts, likely reflective of the older age and the known association with *DTA* mutations.

the Benjamini and Hochberg method. Statistical analyses were conducted in IBM SPSS and SAS software (version 9.4).

## Results

A total of 446 patients with newly diagnosed *NPM1*<sup>+</sup> AML treated on frontline AML protocols at MD Anderson Cancer Center from

2007 to 2019 were identified; 143 patients were excluded because they received induction regimens that could not be classified into HMA, HMA + VEN, or IC, leaving 303 patients for analysis (supplemental Data). Baseline demographics are shown in Table 1. The HMA + VEN group included 28 patients (median age, 71 years); the HMA group, 47 patients (median age, 72 years); and the IC group, 228 patients (median age, 55 years). As

**Table 3. Treatment outcomes**

Treatment group	HMA + VEN, n (%) (n = 28)	HMA, n (%) (n = 47)	Intensive induction, n (%) (n = 228)	P
<b>Response</b>				
CR <sub>c</sub> (CR + CR <sub>i</sub> )	27 (96)	17 (36)*	204 (89)†	<.001* .330†
CR	25 (89)	12 (26)*	193 (85)†	<.001* .778†
CR <sub>i</sub>	2 (7)	5 (11)	11 (5)	—
MRD <sup>−</sup> (multiparameter flow cytometry)	18 (75)	3 (27)*	85 (79)†	.011* .593†
PR	—	—	1 (<1)	—
No response	—	12 (26)	8 (4)	—
30-d mortality	1 (4)	4 (9)	9 (4)	—
Not evaluable	—	1 (2)	—	—
<b>Treatment outcomes by age, y</b>				
<b>CR</b>				
<55	—	—	101/114 (89)	—
55-65	2/2 (100)	1/8 (13)*	78/89 (88)†	.067* 1.00†
>65	23/26 (88)	11/39 (28)*	14/25 (56)†	<.001* .013†
Total	25/28 (89)	12/47 (26)*	193/228 (85)†	<.001* .778†

\*HMA + VEN vs HMA.

†HMA + VEN vs IC.

expected, the IC group had a substantially higher representation of younger patients than either the HMA + VEN or HMA cohort (patients age <55 years: HMA + VEN, n = 0; HMA, n = 0; IC, n = 114; patients age 55-65 years: HMA + VEN, n = 2; HMA, n = 8; IC, n = 89). All groups had a median Eastern Cooperative Oncology Group performance status of 1. A majority of patients had de novo AML (HMA + VEN, n = 25 [89%]; HMA, n = 35 [74%]; IC, n = 213 [93%]), ELN favorable-risk disease (HMA + VEN, n = 24 [86%]; HMA, n = 33 [70%]; IC, n = 183 [80%]), and diploid

cytogenetics (HMA + VEN, n = 23 [82%]; HMA, n = 28 [60%]; IC, n = 173 [76%]).


### Mutational analysis

Patients harbored a median of 4 mutations, as shown in Table 2 (range: HMA + VEN, 1-9; HMA, 1-7; IC, 1-11). *FLT3*-ITD and *DNMT3A* mutations were commonly comutated (HMA + VEN: *FLT3*-ITD, 4 [18%] of 28; *DNMT3A*, 14 [50%] of 28; HMA: *FLT3*-ITD, 28 [60%] of 47; *DNMT3A*, 18 [38%] of 47; IC: *FLT3*-ITD,

**Table 4. Cox multivariate analysis for OS**

OS	HR	95% CI	P	FDR-adjusted P
<b>Treatment group</b>				
HMA vs IC	1.68	0.95-2.98	.076	.076
HMA + VEN vs IC	0.31	0.12-0.83	.019	.038
<b>ELN risk group</b>				
Intermediate vs favorable	1.18	0.59-2.36	.635	—
Adverse vs favorable	1.30	0.80-2.13	.293	—
Age at diagnosis, y	1.04	1.02-1.06	<.0001	—
Secondary AML	1.37	0.76-2.48	.302	—
<b>ECOG performance status</b>				
≥2 vs <2	1.79	1.16-2.76	.009	—
<b>FLT3-ITD</b>				
Positive vs negative	1.55	1.09- 2.21	.016	—

FDR, false discovery rate.



**Figure 2. OS by treatment group in *NPM1*<sup>+</sup> patients treated with HMA + VEN, HMA, and IC.** (A) OS was not significantly different between HMA + VEN vs IC when patients of all ages were included in the analysis (median OS, NR vs 3.7 years;  $P = .292$ ). (B) However, in patients age >65 years, HMA + VEN demonstrated a significant improvement in OS compared with IC (median OS, NR vs 0.9 years;  $P < .001$ ). HMA + VEN outperformed HMA monotherapy, which demonstrated a median OS of 0.4 years (4.8 months).

100 [44%] of 228; *DNMT3A*, 62 [27%] of 228), consistent with prior cohort analyses.<sup>3</sup> *FLT3*-ITD mutations were underrepresented in the HMA + VEN cohort compared with the IC and HMA cohorts. A majority of patients with *FLT3*-ITD mutations had a low allelic ratio (AR; *FLT3*-ITD<sup>+</sup>/WT *FLT3*-ITD < 0.5: HMA + VEN, 4 [100%] of 4; HMA, 20 [71%] of 28; IC, 82 [83%] of 99). *TET2* was also frequently comutated (HMA + VEN, 16 [57%] of 28; HMA, 20 [42%] of 47; IC, 41 [18%] of 228). *IDH1* mutations were identified in 25%, 22%, and 12% of HMA + VEN, HMA, and IC patients, respectively; *IDH2* mutations were identified in 25%, 15%, and 19%, respectively. Patients in each cohort demonstrated a heterogeneous mutational landscape, as shown in Figure 1A-C.

### Mutation effects on outcomes


Outcomes are shown in Tables 3 and 4. In the HMA + VEN, HMA, and IC groups, the CR rate was 89%, 26%, and 85%, respectively. There was no significant difference in CR rates between the HMA + VEN and IC groups (89% vs 85%;  $P = .778$ ), whereas both were significantly improved compared with patients treated with HMA therapy (89% and 85% vs 26%;  $P < .001$ ). CR<sub>c</sub> was seen in 96%, 36%, and 89% of HMA + VEN, HMA, and IC patients, respectively (HMA + VEN vs IC,  $P = .33$ ; HMA + VEN vs HMA,  $P < .001$ ). There was no significant difference in 30-day mortality between groups (HMA + VEN, 4%; HMA, 9%; IC, 4%;  $P = .37$ ). Patients age 55 to 65 years in the HMA + VEN (n = 2), HMA (n = 8), and IC groups (n = 89) had CR rates of 100%, 13%, and 88%, respectively.

Patients age >65 years receiving HMA + VEN (n = 26), HMA (n = 39), and IC (n = 25) had CR rates of 88%, 28%, and 56%, respectively (HMA + VEN vs HMA,  $P < .001$ ; HMA + VEN vs IC,  $P = .013$ ). Among patients achieving a CR who had data available for MRD analysis by flow cytometry (HMA + VEN, n = 24; HMA, n = 11; IC, n = 107), MRD negativity for the HMA + VEN, HMA, and IC groups was 75%, 27%, and 79%, respectively (HMA + VEN vs HMA,  $P = .011$ ; HMA + VEN vs IC,  $P = .593$ ).

VAf of *NPM1* mutations at diagnosis has been associated with OS with conflicting results.<sup>12-14</sup> A total of 170 patients had VAF available for analysis, with a median VAF of 42%. In this cohort, there was a nonsignificant trend toward increased survival seen in patients with VAF < 42% (n = 80) vs those with VAF ≥ 42% (n = 90; median OS, 3.4 vs 2.7 years;  $P = .09$ ).

The favorable prognostic impact of a *NPM1*<sup>+</sup> mutation is context dependent and is particularly influenced by the presence of *FLT3*-ITD comutations. Therefore, this interaction was evaluated specifically, as shown in the multivariate analysis in Table 4. In *NPM1*<sup>+</sup> and *FLT3*-ITD<sup>+</sup> patients, who represented 132 participants (44%), CR was achieved in 100% (4/4), 21% (6/28), and 84% (84/100) of those treated with HMA + VEN, HMA, and IC, respectively (supplemental Data). *FLT3*-ITD<sup>+</sup> patients had inferior outcomes (HR for death, 1.55; 95% CI, 1.09-2.21;  $P = .016$ ) compared with patients with WT *FLT3*, correlating with inferior OS (1.4 vs 3.7 years;  $P = .003$ ), consistent with the known prognostic effect





**Figure 3. OS in ELN favorable-risk patients.** (A) HMA + VEN demonstrated improved OS in patients age >65 years compared with both HMA and IC (median OS, NR vs 0.5 vs 1.0 years;  $P < .001$  and .005, respectively). (B) HMA + VEN continued to be associated with a significant improvement in OS in ELN favorable-risk patients age >60 years.

of *FLT3*-ITD mutations.<sup>3</sup> In the setting of *NPM1*<sup>+</sup>, no significant difference in median OS was identified based on the AR (high, >0.5; low, <0.5) of *FLT3*-ITD<sup>+</sup> (low AR (n = 107), 1.4 years vs high AR (n = 25), 1.1 years;  $P = .12$ ). Analysis of *FLT3*-ITD<sup>+</sup> patients treated with a *FLT3* inhibitor (n = 56 [sorafenib, n = 53; quizartinib, n = 1; midostaurin, n = 2]) demonstrated similar OS vs *FLT3*-ITD<sup>+</sup> patients not receiving a *FLT3*i (n = 76; median OS: *FLT3*-ITD<sup>+</sup>/*FLT3*i, 1.4 years vs *FLT3*-ITD<sup>+</sup>, 1.2 years;  $P = .77$ ). However, IC patients treated with a *FLT3*i had significant improvement in OS compared with those *FLT3*<sup>+</sup> patients not receiving a *FLT3*i (n = 76; median OS: *FLT3*<sup>+</sup>/*FLT3*i, 4.7 years vs *FLT3*<sup>+</sup>/no *FLT3*i, 1.4 years;  $P = .018$ ).

A trend toward decreased survival was also seen among patients with triple-mutated *NPM1*/*FLT3*-ITD/*DNMT3A* when compared with patients without *FLT3*-ITD or *DNMT3A* mutations regardless of treatment regimen (median OS: *NPM1*/*DNMT3A*/*FLT3*-ITD, 1.6 years vs 3.6 years;  $P = .07$ ). In the setting of WT *FLT3*, *DNMT3A* mutations had no significant impact on OS in *NPM1*<sup>+</sup> patients ( $P = .97$ ).


### Impact of age on survival

OS decreased incrementally in *NPM1*<sup>+</sup> patients age <55, 55 to 65, and >65 years (median OS, 5.0, 4.4, and 0.9 years, respectively). A noteworthy difference in OS was identified in IC-treated patients age ≤65 years compared with those age >65 years (median OS, 4.4 years vs 11.2 months;  $P < .001$ ). Because older AML patients are more likely to harbor complex cytogenetics and have adverse-risk disease, even in the context of *NPM1*<sup>+</sup>, this analysis was repeated only for ELN favorable-risk patients (n = 240) with similar findings (median OS: age ≤65 years, 5.1 years vs age >65 years, 1.0 year;  $P < .001$ ).

Assessing the impact of treatment regimen on OS in all patients irrespective of age or fitness, there was a significant increase in OS with HMA + VEN vs HMA (median OS, NR vs 0.4 years;  $P < .001$ ), whereas no significant difference was observed between HMA + VEN and IC (median OS, NR vs 3.7 years;  $P = .292$ ). After adjusting for multiple factors by multivariable Cox model analysis (Table 4), HMA + VEN therapy was associated with a significant reduction in risk of death compared with IC (HR, 0.31; type I error-adjusted  $P = .038$ ) after considering other important clinical factors in the model. Furthermore, median OS in the subgroup of patients age >65 years was significantly improved in those treated with HMA + VEN vs HMA (NR vs 0.4 years;  $P < .001$ ) and in those treated with HMA + VEN vs IC (NR vs 0.93 years;  $P = .001$ ; Figure 2). Among ELN favorable-risk *NPM1*<sup>+</sup> patients age >65 years, HMA + VEN was associated with improved survival (median OS, NR) compared with HMA (0.5 years;  $P < .001$ ) or IC (median OS, 0.99 years;  $P = .001$ ), as shown in Figure 3.

Because of the known interactions of *FLT3*-ITD and impact of *FLT3*i in *FLT3*-ITD<sup>+</sup> patients, we analyzed survival in the subgroup of *NPM1*<sup>+</sup> and *FLT3*-ITD<sup>-</sup> patients separately (Figure 4). In the analysis of older *FLT3*-ITD<sup>-</sup> patients, HMA + VEN maintained a significantly improved OS compared with HMA or IC (median OS, NR vs 6 vs 10.8 months;  $P < .01$ ), which compares favorably with the OS observed in prior studies of *NPM1*<sup>+</sup>/*FLT3*-ITD<sup>-</sup> AML.<sup>11</sup>

The favorable outcome of patients with *IDH1* and *IDH2* mutations in the setting of VEN-based regimens has additionally been reported,<sup>21,22</sup> although their prognostic importance in the setting of IC has been more challenging to delineate and remains a matter of some debate.<sup>23</sup> In the entire cohort of *NPM1*<sup>+</sup> patients, those with cooccurring *IDH1*



**Figure 4. OS *FLT3*-ITD<sup>-</sup>/*FLT3*i<sup>-</sup> was assessed, given the known frequent cooccurrence of *FLT3*-ITD mutations in *NPM1*<sup>+</sup> AML and the emerging data demonstrating improved OS in patients receiving an *FLT3*i.** (A) No difference in OS was seen in patients of all ages treated with HMA + VEN vs IC (median OS, NR vs 5.7 years;  $P = .303$ ). (B) In patients age >65 years, HMA + VEN continued to demonstrate improved OS compared with IC (median OS, NR vs 0.9 years;  $P = .008$ ). In both age groups, HMA + VEN and IC significantly outperformed HMA monotherapy (median OS, 0.5 years).

mutations ( $n = 44$ ) had an OS of 1.2 years (vs 2.5 years for WT *IDH1*) and those with *IDH2*-R140 mutations ( $n = 58$ ) had an OS of 3.4 years (vs 2.2 years for WT *IDH2*), which is of interest, although neither group reached statistical significance ( $P = .26$  and  $P = .39$ , respectively). No *IDH2* R172 mutations were identified in this cohort of *NPM1*<sup>+</sup> AML.

Subgroup analysis of patients treated with IC with *IDH* mutations (*IDH1*,  $n = 24$ ; *IDH2*,  $n = 40$ ; *IDH1/2*,  $n = 4$ ) demonstrated no significant difference in OS (median OS: *IDH1*, 6.7 years; *IDH2*, 3.7 years; WT, 3.5 years;  $P =$  nonsignificant [NS]), whereas those with dual *IDH1/IDH2* mutations had inferior OS (median OS, 0.6 years;  $P \leq .01$  across all 3 comparator groups). *IDH1/2* mutations also had no significant impact on OS in patients treated with HMA therapy (median OS: *IDH1*, 0.4 years; *IDH2*, 0.2 years; *IDH1/2*, 0.9 years; WT, 0.5 years;  $P =$  NS). Median OS was not reached in patients with *IDH1* or *IDH2* mutations treated with HMA + VEN. Estimated 1-year OS was 75%, 100%, and 55% for patients with *IDH1*, *IDH2*, and WT *IDH*, respectively. CR rates were particularly high in *NPM1*<sup>+</sup> patients with *IDH1* mutations (6 [86%] of 7) and with *IDH2* mutations (6 [100%] of 6) treated with HMA + VEN.

## Discussion

With the recent approval of multiple new therapeutic options for patients with AML, the choice of treatment regimen to optimize patient outcomes can be challenging. This is especially true in older patients with AML, in whom outcomes regardless of fitness have remained historically poor. AML with *NPM1*<sup>+</sup> is common, representing approximately one-third of all AMLs, and is associated

with more favorable-risk disease and chemotherapy responsiveness; however, this favorable outcome is substantially muted in older *NPM1*<sup>+</sup> patients. Whether novel lower-intensity regimens may offer similar or even improved outcomes with improved patient tolerance and quality of life is an essential question in the current treatment era. Therefore, given recent reports delineating exquisite sensitivity of *NPM1*<sup>+</sup> AML to VEN-based treatment regimens,<sup>21,24</sup> we sought to determine the outcomes of *NPM1*<sup>+</sup> AML patients, with a focus on older patients receiving various treatment strategies, particularly the outcomes of patients receiving HMA + VEN, as compared with historical standard-of-care therapies (IC or HMA monotherapy).

In this study, in multivariate analysis, HMA + VEN was associated with a 69% lower risk of death compared with IC (HR, 0.31; 95% CI, 0.12-0.83;  $P = .038$ ). Older patients age >65 years with *NPM1*<sup>+</sup> AML treated with either decitabine or azacitidine combined with VEN achieved a high CR rate compared with patients receiving intensive induction regimens (88% vs 56%;  $P = .01$ ) and had significantly improved OS (NR vs 0.4 vs 0.9 years) compared with HMA monotherapy or intensive induction therapy. After a median follow-up of 1 year, 80% ( $n = 21$ ) of patients age >65 years treated with HMA + VEN were alive, compared with 36% ( $n = 9$ ) of patients treated with IC and 12% ( $n = 1$ ) of patients treated with HMA. These results compare favorably with prior retrospective analyses of older patients treated with IC and provide further evidence of the improved outcomes using HMA combinations over HMA monotherapy in the treatment of AML.<sup>7,11,16</sup>



Given the known negative prognostic effect of co-occurring *FLT3*-ITD mutations on outcomes of *NPM1*<sup>+</sup> patients,<sup>3,25,26</sup> as well as the potential therapeutic synergy between BCL-2 inhibition and *FLT3* inhibition, *FLT3*-ITD mutations were included in a multivariate model comparing treatment regimens for OS. Additionally, sensitivity analyses were performed after excluding *FLT3*-ITD<sup>+</sup> patients and those treated with an *FLT3*i, which may have altered the results. Regardless of *FLT3*-ITD status and use of an *FLT3*i, HMA + VEN combinations continued to demonstrate improved outcomes in older AML patients.

HMA + VEN is effective in adult patients with *NPM1*<sup>+</sup> AML. In patients age >65 years with *NPM1*<sup>+</sup> AML, frontline HMA + VEN therapy was associated with CR rates >85% and low (<5%) treatment-related mortality. Additionally, MRD negativity by flow cytometry was achieved in a substantial portion of patients treated with HMA + VEN, indicating this regimen can induce deep MRD<sup>−</sup> remissions.

Older HMA + VEN patients had an OS of 80% after a median 1 year of follow-up, with an estimated 2-year OS of 70%. Outcomes in this subgroup were significantly improved compared with contemporaneous patients receiving IC, suggesting HMA + VEN is a well-tolerated and effective treatment option in this patient population. Only a few patients age <60 years with *NPM1*<sup>+</sup> mutations were treated with HMA + VEN therapy. Although HMA + VEN therapy in these patients seemed to have efficacy similar to that of intensive induction, further follow-up evaluating the long-term outcomes is warranted before HMA + VEN therapy is considered a standard therapeutic option for younger, fit patients with AML.

Limitations of the study included the retrospective nature of the analysis, in addition to the small sample size in the HMA + VEN and HMA cohorts. Furthermore, *FLT3*-ITD mutations were underrepresented in the HMA + VEN cohort. These results must therefore be interpreted in the context of these limitations. Randomized prospective studies are ongoing to assess the role of HMA + VEN as a standard-of-care therapy in older, fit adults.

In conclusion, we confirm the sensitivity of *NPM1*<sup>+</sup> AML to HMA + VEN combinations and suggest this regimen could be considered as an optimal mutation-targeted treatment approach for older patients with AML and *NPM1* mutations.

## Authorship

Contribution: C.A.L. aided in data analysis and preparation of the manuscript; W.Q. and J.N. aided in data analysis; C.D.D. and M.K. aided in data collection and analysis and preparation of the manuscript; and S.L., T.M.K., N.D., G.B., N.P., K.N., Y.A., M.Y., N.S., M.O., S.R.P., K.P.P., E.J., M.A., F.R., H.M.K., K.S., and K.T. aided in data collection and review of the manuscript.

Conflict-of-interest disclosure: C.D.D. reports research funding from AbbVie, Agios, Celgene, and Daiichi Sankyo and consultancy and advisory roles for AbbVie, Agios, Celgene, Daiichi Sankyo, and Notable Labs. M.K. reports consulting and research funding from AbbVie, Genentech, F. Hoffman-La Roche. T.M.K. reports research funding and honoraria from AbbVie. N.D. reports research funding and consultancy from AbbVie and Genentech. N.P. reports consulting/honoraria from AbbVie, Celgene, Stemline, Incyte, Novartis, MustangBio, Roche Diagnostics, and LFB; research funding and clinical trial support from Stemline, Novartis, AbbVie, Samus, Cellectis, Plexxikon, Daiichi Sankyo, and Affymetrix; grants and funding from Affymetrix and SagerStron Foundation; and noncompensated board memberships for Dan's House of Hope and HemOnc Times/Oncology Times. M.A. reports research funding from AbbVie. F.R. reports research funding and honoraria from AbbVie. H.M.K. reports research funding from AbbVie, Agios, Amgen, Ariad, Astex, Bristol-Myers Squibb, Cyclacel, Daiichi Sankyo, Immunogen, Jazz Pharma, Novartis, and Pfizer and honoraria support from AbbVie, Actinium (advisory board), Agios, Amgen, Pfizer, and Takeda. The remaining authors declare no competing financial interests.

ORCID profiles: C.A.L., 0000-0001-8506-0624; S.L., 0000-0001-8980-3202; N.D., 0000-0001-7103-373X; Y.A., 0000-0002-1652-7937; K.P.P., 0000-0001-5081-2427; K.S., 0000-0002-9140-0610; M.A., 0000-0002-1144-1958; H.M.K., 0000-0002-1908-3307; M.K., 0000-0002-9347-2212; C.D.D., 0000-0001-9003-0390.

Correspondence: Courtney D. DiNardo, Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030; e-mail: cdinardo@mdanderson.org.

## References

- Colombo E, Marine JC, Danovi D, Falini B, Pelicci PG. Nucleophosmin regulates the stability and transcriptional activity of p53. *Nat Cell Biol*. 2002;4(7):529-533.
- Falini B, Mecucci C, Tiacci E, et al; GIMEMA Acute Leukemia Working Party. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. *N Engl J Med*. 2005;352(3):254-266.
- Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. *N Engl J Med*. 2016;374(23):2209-2221.
- Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of *NPM1* mutations in 1485 adult patients with acute myeloid leukemia (AML). *Blood*. 2006;107(10):4011-4020.
- Nagel G, Weber D, Fromm E, et al; German-Austrian AML Study Group (AMLSG). Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). *Ann Hematol*. 2017;96(12):1993-2003.
- Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. *N Engl J Med*. 2012;366(12):1079-1089.
- Mrózek K, Marcucci G, Nicolet D, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. *J Clin Oncol*. 2012;30(36):4515-4523.

8. Schlenk RF, Döhner K, Krauter J, et al; German-Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. *N Engl J Med*. 2008;358(18):1909-1918.
9. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood*. 2017;129(4):424-447.
10. Tallman MS, Wang ES, Altman JK, et al; OCN. Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology. *J Natl Compr Canc Netw*. 2019;17(6):721-749.
11. Ostronoff F, Othus M, Lazenby M, et al. Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report. *J Clin Oncol*. 2015;33(10):1157-1164.
12. Patel SS, Kuo FC, Gibson CJ, et al. High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. *Blood*. 2018;131(25):2816-2825.
13. Linch DC, Hills RK, Burnett AK, Russell N, Gale RE. Analysis of the clinical impact of NPM1 mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia [published online ahead of print 8 October 2019]. *Br J Haematol*. doi:10.1111/bjh.16239.
14. Abbas HA, Ravandi F, Loghavi S, et al. NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia. *Am J Hematol*. 2019;94(6):E158-E160.
15. Lübbert M, Rüter BH, Claus R, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. *Haematologica*. 2012;97(3):393-401.
16. Prata PH, Bally C, Prebet T, et al. NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents. *Haematologica*. 2018;103(10):e455-e457.
17. Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. *Blood*. 2015;126(3):291-299.
18. Martelli MP, Gionfriddo I, Mezzasoma F, et al. Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. *Blood*. 2015;125(22):3455-3465.
19. Schlenk RF, Döhner K, Kneba M, et al. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. *Haematologica*. 2009;94(1):54-60.
20. Nazha A, Bueso-Ramos C, Estey E, et al. The addition of all-trans retinoic acid to chemotherapy may not improve the outcome of patient with NPM1 mutated acute myeloid leukemia. *Front Oncol*. 2013;3:218.
21. DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naïve, elderly patients with acute myeloid leukemia. *Blood*. 2019;133(1):7-17.
22. Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. *Nat Med*. 2015;21(2):178-184.
23. DiNardo CD, Ravandi F, Agresta S, et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. *Am J Hematol*. 2015;90(8):732-736.
24. Bisailon R, Moison C, Thiollier C, et al. Genetic characterization of ABT-199 sensitivity in human AML. *Leukemia*. 2020;34(1):63-74.
25. Sakaguchi M, Yamaguchi H, Najima Y, et al. Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia. *Blood Adv*. 2018;2(20):2744-2754.
26. Lazenby M, Gilkes AF, Marrin C, Evans A, Hills RK, Burnett AK. The prognostic relevance of FLT3 and NPM1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial. *Leukemia*. 2014;28(10):1953-1959.